NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization105.16 mln
Float7.22 mln
Earnings Date08/19/2026
1-Year Forecast
18.71
Transformational upside
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.02
Debt-free
ROE
-72.00
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Founded in 2019 and based in Berkeley Heights, New Jersey, Kalaris Therapeutics is a medical company focused on developing new treatments for serious eye diseases that affect the retina. Its lead drug candidate, TH103, targets abnormal blood vessel growth in the eye and is currently being tested in mid-stage clinical trials as a potential treatment for age-related macular degeneration and similar conditions. The company was previously known as Theia Therapeutics before adopting its current name in May 2024.
